Abstract Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cell activation. Even though novel therapeutic tools have emerged, CyA still represents a suitable option in several clinical rheumatology settings. This is the case of refractory nephritis and cytopenias associated with systemic lupus erythematosus.
Introduction
The earliest use of cyclosporine A (CyA) in the field of rheumatology dates back to 1979, when the first trial in patients with inflammatory arthritides was conducted [1] . Since then, CyA has been used to manage several autoimmune conditions: thanks to its mechanism of action, this pharmacological compound is potentially effective in different clinical settings.
Mechanism of Action of Cyclosporine A
Initially developed as an anti-mycotic agent, CyA is an 11-aminoacid peptide originally isolated from a soil fungus. Its immunosuppressive properties have been described in the 1970s, when it was first employed as an anti-rejection agent for organ transplantation. CyA is a pro-drug, which becomes active after complexing with cyclophillin, an intracytoplasmatic protein. The CyA-cyclophillin complex in turn inhibits calcineurin, a phosphatase that mediates the pharmacological effects of CyA. Indeed, calcineurin induces the translocation into the nucleus of the nuclear factor of activated T cells (NF-AT), which acts as transcription factor for a number of proinflammatory cytokines, such as interleukin (IL)-2, IL-2 receptor, IL-4, interferon (IFN)-γ and transforming growth factor-β (TGF-β). The inhibition of IL-2 and IL-2 receptor, the two main stimulating pathways involved in T cell activation, accounts for the action of CyA on T cells: it impairs the activation of T helper (Th) cells, even though the T suppressor (Ts) subset may also be affected [2] . The pharmacological action of CyA is schematically presented in Fig. 1 .
Pharmacokinetics of Cyclosporine A
Two formulations of CyA have been developed: the original one (Sandimmune) displays a poor bioavailability and larger inter-and intra-subject pharmacokinetic variability; the most recent microemulsion (Neoral) offers a better bioavailability and a more predictable pharmacokinetics and dose linearity. Because of its lipophilic nature, plasma CyA is almost exclusively bound to lipoproteins, explaining why CyA serum concentrations might be affected by dietary fat intake. Indeed, raised serum lipid levels can increase CyA total body clearance: a higher serum CyA concentration results when the drug is administered before rather than after meals, accounting for higher clinical efficacy [2] .
CyA displays a first-pass effect of 27 % in the liver; the enterohepatic recirculation of CyA from the bile to the small intestine is responsible for its biphasic distribution. CyA halflife in serum ranges between 6 and 24 h; its oral bioavailability and systemic clearance are controlled by the cytochrome P450 and the efflux p-glycoprotein pump, a trans-membrane transporter expressed in the gastrointestinal tract and in the liver. CyA metabolites are excreted primarily in the bile, with only 6 % of the dose being excreted in the urine [2] .
Cyclosporine A in Rheumatoid Arthritis
The rationale of CyA use in rheumatoid arthritis (RA) is supported by its mechanism of action: besides the inhibition of T cells, CyA has been demonstrated to suppress IL-17 production in vitro. This results in the impairment of the differentiation of Th17 cells, a distinct lineage of pro-inflammatory Th cells regarded as key effectors in RA pathogenesis [3] . The 2008 updated guidelines issued by the American College of Rheumatology (ACR) do not enlist CyA as a therapeutic option in the management of RA [4] . As a matter of fact, evidences about CyA efficacy in RA are not recent and not so solid to support its routine use (Table 1) . Over the years, CyA has been proven to be more effective than placebo in disease control [5] [6] [7] [8] [9] , even at long term [10] , delaying radiological progression [11] [12] [13] . Controlled trials have shown CyA to be as effective as parenteral gold [14, 15] , D-penicillamine [16] , hydroxychloroquine (HCQ) and azathioprine (AZA) [17] [18] [19] , but less effective than methotrexate (MTX) [20] [21] [22] .
Combining CyA with HCQ, chloroquine or gold has been observed to convey no clear benefit [23] [24] [25] [26] . Conversely, association regimens comprising CyA plus MTX have been demonstrated to allow a greater rate of disease control as 2+ calcium, NF-ATc-P phosphorylated cytoplasmic nuclear factor of activated T cells, NF-ATc cytoplasmic nuclear factor of activated T cells, NF-ATn nuclear nuclear factor of activated T cells, IL-2 interleukin 2 compared with CyA monotherapy [27] [28] [29] [30] and CyA plus leflunomide (LEF) [31] , using a step-up or a step-down approach. Clinical studies have investigated the combination regimen of CyA plus MTX to MTX alone, reporting a greater beneficial effect for the combo approach [32] [33] [34] , a benefit not sustained on the long term [35] . Consistently, MTX non responder patients have been shown to present a better disease course when randomised to MTX plus CyA than when receiving MTX plus placebo [36, 37] . On the other hand, the addition of CyA to MTX and infliximab (IFX) has been proven to result only in a modest increase in the response [38, 39] , even though CyA plus MTX association regimen has been shown to be effective in maintaining disease remission after suspension of treatment with tumour necrosis factor (TNF) inhibitors in 62 % of patients [40] , avoiding even erosive progression at MRI [41] . A 2001 meta-analysis of randomised controlled trials (RCT) evaluating the optimal step-up strategy in patients with an incomplete response to MTX has found that the addition of CyA, etanercept (ETN), IFX or LEF results in a comparable ACR20 response at 24-30 weeks of combination therapy [42] .
Cyclosporine A in Psoriatic Arthritis
CyA has been shown to be more effective in the management of psoriatic arthritis (PsA) as compared with RA [43] . Such observation might be explained by the pivotal role played by IL-17 axis in PsA pathogenesis. Furthermore, CyA inhibits vascular endothelial growth factor (VEGF), a key mediator of the angiogenesis characteristic of PsA rather than RA synovium [44, 45] . In the 2008 treatment guidelines for PsA, CyA is recommended in the management of moderate or severe peripheral arthritis, moderate to severe skin and nail disease [46] . Clinical improvement becomes usually evident after 3-4 weeks of treatment with CyA; response of both skin and joint involvement is dose-related, with the lowest optimal effective maintenance dose being around 3 mg/kg. Observational studies have shown CyA to exert a beneficial effect in reducing peripheral (but not axial) joint involvement in patients with PsA [47] [48] [49] [50] . Controlled trials have reported that CyA is as effective as MTX, but with a higher withdrawal rate [51] , and more effective than sulfasalazine (SSZ) [52] . The association of CyA with MTX has been shown to lead to a significantly better joint disease control than MTX alone [53] ; the addition of CyA to ETN in patients with PsA and uncontrolled cutaneous disease has emerged to be a safe and effective therapeutic option [54] , being even better on psoriatic skin involvement than ETN plus MTX [55] . Response to CyA in PsA has been found to be persistent at 2-year follow-up [56] , controlling also the radiological damage [57] . Clinical studies on CyA in PsA are detailed in Table 2 .
Cyclosporine A in Systemic Lupus Erythematosus
In vivo, treatment with CyA has been found to prolong the life span of NZB/W F1 mice, reducing anti-DNA antibody titers [58] [59] [60] . The earliest experience with CyA treatment in patients with systemic lupus erythematosus (SLE) dates back to 1981; nowadays, CyA is not so commonly prescribed to lupus patients. In several small observational studies, CyA, alone or in combination with other agents, has been shown to reduce disease activity and improve immunological parameters such as anti-double-stranded DNA (anti-dsDNA) titers and complement levels, allowing steroid tapering [61] [62] [63] [64] [65] [66] [67] [68] [69] ( Table 3 ). In particular, CyA has been shown to be beneficial in some lupus manifestations, and it might be taken into account as therapeutic option in refractory lupus nephritis, skin disease and haematological involvement [70] . CyA efficacy in lupus nephritis is mediated not only by its immunosuppressive action but also its ability to stabilise the podocyte cytoskeleton by inhibiting dephosphorylation and degradation of synaptopodin, an actin-associated protein that regulates cell shape and motility and mediates podocyte foot processes. To note, synaptopodin downregulation and increased calcineurin activity are both associated with proteinuric glomerular diseases [71, 72] . CyA is currently recommended in the management of lupus nephritis with persistent severe proteinuria, refractory to conventional treatment with corticosteroids and cytotoxic agents [70] . Indeed, according to still limited data, the association of CyA with corticosteroid therapy is effective in the treatment of class III, IV or V lupus nephritis. Most evidence suggests CyA efficacy in proliferative lupus nephritis, as supported by few case series [66, [73] [74] [75] [76] [77] [78] and uncontrolled trials [79, 80] . In addition, CyA has been shown to be more beneficial than steroids alone [81] and as effective as AZA [82] and cyclophosphamide (CTX), both at short [83] and long-term follow-up [84] . As a whole, it can be stated that CyA treatment in proliferative lupus nephritis displays a cumulative rate of complete or partial remission approaching 90 %, with an important anti-proteinuric effect [85] . CyA has been proven to be effective also in the management of membranous lupus nephritis, even though evidence comes from small retrospective studies [86] [87] [88] [89] and a single RCT comparing CyA with CTX as adjunctive treatments to steroids [90] . A 2014 meta-analysis considering CyA and tacrolimus has concluded that calcineurin inhibitors might be regarded as a reasonable alternative to CTX in the induction treatment of active lupus nephritis, with an higher rate of complete remission (relative risk (RR) = 1.56) and a better response/ total remission ratio (RR = 1.23) [91] . On the other hand, when evaluating prescription of CyA in lupus nephritis, it should be mentioned that in a cross-sectional study on 64 patients with lupus nephritis, CyA treatment has emerged as a risk factor for arterial hypertension, conveying a odds ratio of 5.3 [92] . CyA cyclosporine A, CTX cyclophosphamide, PDN prednisone, MTX methotrexate, AZA azathioprine, MMF mycophenolate mofetil, PE plasma exchange, SLE systemic lupus erythematosus, LE lupus erythematosus, SLEDAI systemic lupus erythematosus disease activity index, NR not reported, ANA anti-nuclear antibodies, anti-dsDNA anti-double-stranded DNA antibodies
Haematological abnormalities, if relapsing or refractory to steroids, have been shown to respond well to CyA. This is the case of lupus-associated thrombocytopenia [93, 94] , haemolytic anaemia [95] , aplastic anaemia [96] , red cell aplasia [97] [98] [99] and haemophagocytic syndrome [100] . Unfortunately, literature is still limited to case reports and small case series.
CyA exerts an evident steroid-sparing effect in cutaneous lupus. Unfortunately, skin disease has not provided a primary outcome measure in most studies in SLE; however, cutaneous manifestations have been reported to improve upon CyA treatment [65, 68] . In addition, there are case reports of CyA efficacy in subacute cutaneous lupus erythematosus (LE) [101] and LE profundus [102] , but not in discoid LE [103, 104] .
Cyclosporine A in Systemic Sclerosis
In vitro, CyA has been observed to inhibit the pro-fibrotic effects induced by TGF-β and IL-4 in fibroblasts, leading to a decreased synthesis of collagen [105] [106] [107] . Although there is a rationale for its use, data in support of the efficacy of CyA in systemic sclerosis (SSc) are not solid (Table 4) . CyA has been reported to significantly improve skin thickening in some, but not all, scleroderma patients; available evidence comes from small, short-term studies [69, [108] [109] [110] [111] . In particular, an improvement of oesophageal motor function has emerged with CyA treatment [111, 112] ; conversely, CyA has been described not to affect scleroderma-related internal organ involvement, in particular lung and cardiac disease [108] . There is a single report of the benefit of CyA in interstitial lung disease (ILD): one patient with diffuse scleroderma received CyA as maintenance therapy after CTX pulses, with evidences of stable disease at 2-year clinical and radiological follow-up [113] . It is thus not surprising that the guidelines for scleroderma treatment published by the European League Against Rheumatism Scleroderma Trials and Research Group have not recommend CyA in SSc, highlighting the need of larger prospective studies [114] . It should be noted that CyA use in SSc is limited by its nephrotoxicity: indeed, CyA might affect renal function through a direct toxic action on the nephron or through an impairment of renal haemodynamic homeostasis. Consequently, CyA may not only worsen arterial hypertension, but also precipitate acute renal failure. In the past, CyA has even been proposed as risk factor for scleroderma renal crisis, but such association has not been confirmed in later studies [115] .
Cyclosporine A in Inflammatory Myopathies
In the setting of inflammatory myopathies (polymyositis (PM) and dermatomyositis (DM)), CyA is currently regarded as a second-line option to be reserved to patients with disease refractory to standard regimen, which includes high-dose prednisone plus MTX or AZA.
Few trials have investigated CyA efficacy in inflammatory myopathies (Table 5 ). In a prospective controlled study, ten DM patients receiving CyA have achieved a prompt remission; therapeutic failure occurred in 10 % of cases as compared with 9 % in those treated with standard regimen [116] . In addition, in a RCT on 36 patients (20 with DM, 16 with PM), CyA has been shown to be as effective as MTX [117] . In literature, there are reports about CyA efficacy in managing DM-associated oesophageal involvement [118] . A growing body of evidence suggests the beneficial effect of CyA in CyA cyclosporine A, SRC scleroderma renal crisis, CS case series, PC prospective cohort, CR case report, RCT randomised controlled trial the management of ILD [119] [120] [121] [122] [123] , also in cases resistant to steroid treatment [124, 125] and those with an acute onset [126] . In particular, disease stabilisation-or even an increase greater than 10 % in forced vital capacity-has been reported in all series. CyA has also been compared with CTX in the management of PM/DM-ILD: in a cohort of 15 anti-Jo1-positive patients with lung involvement, high resolution scan of the chest at 12-month follow-up has revealed a disease worsening in 71 % of patients treated with CyA as compared with 50 % of those receiving CTX, with no differences in CT changes [127] .
Cyclosporine A in Systemic Vasculitides
CyA is not enlisted as a therapeutic option in the current guidelines for the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides: the evidence of CyA efficacy in these clinical settings is rather scarce (Table 6 ). There are only anecdotal reports of patients with refractory granulomatosis with polyangiitis (GPA; formerly known as Wegener granulomatosis) successfully treated with
CyA. In particular, CyA has led to the improvement of renal function and to the complete resolution of lung lesions [128] [129] [130] , while in other cases CyA has not been effective in achieving disease remission [131] . A single report of CyA in eosinophilic granulomatosis with polyangiitis (EGP; formerly known as Churg-Strauss syndrome) has been published: a patient with EGP resistant to treatment with pulse intravenous CTX responded well to CyA therapy [132] . Similarly, the burden of evidence suggesting CyA efficacy in large vessels vasculitides is poor. In a RCT, CyA has been evaluated as steroid-sparing agent in 22 patients with giant cells arteritis. However, the addition of CyA to corticosteroid treatment does not appear to be beneficial [133] [134] [135] . CyA has been successfully used in the management of patients with Takayasu's arteritis [134, 136] , in particular in those subjects with severe pyoderma gangrenosum [137, 138] .
Cyclosporine A in Behçet's Disease
The efficacy of CyA in Behçet's disease (BD) is supported by the inhibition of IL-1, a key cytokine in disease pathogenesis [139] . Given the wide heterogeneity in the clinical manifestations of BD, the therapeutic approaches might be rather diverse, depending upon the presenting symptoms. Even though CyA has been shown to be effective in almost all clinical manifestations of BD, its use is currently recommended in the management of refractory ocular involvement and thrombophlebitis [140] (Table 7) . In particular, refractory eye disease provides the main setting for CyA prescription in BD. Indeed, CyA is the agent of choice, alternatively to IFX, in the management of eye involvement not responsive to standard treatment, to be prescribed in combination with AZA and corticosteroids [140] . This recommendation is supported by three RCT concordantly showing CyA efficacy in ocular involvement [141] [142] [143] , even though to a lower extent than IFX [144] . To note, CyA is rapidly effective in acute uveitis, although the beneficial effects seem to be not sustained in the long term [145, 146] .
CyA is currently recommended also in the management of thrombophlebitis, based on an open trial showing complete resolution of venous insufficiency with no recurrences over a 2-month follow-up in seven patients [147] . In addition, CyA has been demonstrated to be effective in case of ulcers, oral as well as genital, and erythema nodosum, being superior to colchicine [143, 148] . However, CyA is regarded as fourth-line agent because of its toxicity profile. In particular, because of its neurotoxicity, CyA should be not prescribed to BD patients with central nervous system involvement, unless necessary to manage intraocular inflammation [140] . CyA neurologic side effects in BD have been confirmed in three case-controlled studies [149] [150] [151] .
Cyclosporine A in Adult Onset Still's Disease
Corticosteroids still provide the mainstay of treatment of adult onset Still's disease, and MTX is the first-line steroid-sparing option. Targeted biologic agents, mainly IL-1 antagonists and TNF-α inhibitors, are reserved to refractory cases [152] . Even though there are reports of CyA efficacy as steroid-sparing agent with a rapid effect and a low recurrence rate [153] , its use in adult onset Still's disease is currently limited to some of the severe manifestations of Still's disease [154] . Indeed, CyA, alone or in combination with other pharmacological tools, might be considered as an option in the management of disseminated intravascular coagulation [155, 156] , macrophage activation syndrome (MAS) [157, 158] , acquired amegakariocytic thrombocytopenia [159] and severe hepatic failure [160] . Details of studies investigating CyA in adult onset Still's disease are presented in Table 8 .
Cyclosporine A in Sjogren's Syndrome
Ex vivo studies have showed that topical CyA therapy induces a reduction in the number of activated T lymphocytes and apoptotic cells in conjunctival biopsies, a decreased expression of pro-inflammatory cytokines and a raise in goblet cell epithelial density [161] [162] [163] . Topical CyA is currently recommended in the management of dry eye (symptoms severity of level 2) associated with Sjogren's syndrome, at the dose of one drop in each eye twice daily [164] . Indeed, almost all available RCT have reported topical CyA to improve symptoms and signs of ocular sicca syndrome as compared with placebo or alternative treatment [165] [166] [167] [168] [169] . No clear dose-response CyA more effective than conventional treatment in the management of ocular manifestations of BD Masuda [143] 1989 RCT 10 mg kg
16 weeks CyA, colchicine CyA more effective than colchicine in reducing the frequency and severity of ocular attacks, of oral aphthous ulcer and dermal lesions Ozyazgan [141] 1992 CC 5 mg kg −1 day −1 23 34 months CyA, CTX CyA more effective than CTX in the management of BD-associated uveitis at 6 months Avci [148] 1997 CS 5 mg kg −1 day −1 24 6 months CyA CyA effective on mucocutaneous manifestations of BD Cantini [147] 1999 PC 5 mg kg −1 day Oral CyA has been evaluated in a single double-blind study conducted in a cohort of 20 patients, with a significant improvement of xerostomia and no significant differences in the Schirmer test score [170, 171] . Details of studies investigating CyA in Sjogren's syndrome are presented in Table 9 .
Cyclosporine A in Paediatric Rheumatology
CyA is currently used even in the field of paediatric rheumatology, with two particular indications: juvenile DM (JDM) and systemic juvenile idiopathic arthritis (sJIA). Few small retrospective studies and case series have investigated the beneficial effects of CyA in JDM. Even though corticosteroids are the only agents currently approved by the US Food and Drug Administration for JDM, many patients require additional immunosuppressive medications. In JDM patients unresponsive to corticosteroids or immunosuppressive drugs (MTX, AZA or CTX), CyA treatment has resulted in the improvement of muscle strength, allowing steroid tapering [172] [173] [174] . None of the immunosuppressive drugs have been yet evaluated in controlled trials in children; a 5-year, phase-III, single-blind, randomised, controlled trial is currently on-going. It envisages three treatment arms: (i) prednisone, (ii) prednisone plus MTX and (iii) prednisone plus CyA. This international trial involves 185 partners from 46 countries, coordinated by Paediatric Rheumatology International Trials Organisation (PRINTO) and conducted in children with newly diagnosed JDM. An analysis of primary outcome measures after 6 months of treatment has showed that time to inactive disease is significantly shorter and time to major therapeutic changes significantly longer in the combination groups compared with prednisone alone. The highest rate of adverse events has been registered in the group treated with CyA (51 %) compared with MTX (28 %) or prednisone alone (21 %) [175] .
The guidelines issued by ACR in 2013 recommends CyA as third-line treatment for sJIA children with active systemic features and a physician global assessment higher than 5 [176] . This recommendation is based upon prospective and retrospective series that have showed that CyA is effective in treatment of sJIA, leading to improvement in laboratory variables, joint counts, joint swelling and morning stiffness in some-but not all-children, even if the improvement is not sustained at long term [173, 174, 177, 178] . CyA has been evaluated even as second-line tool in sJIA, showing a good efficacy when associated with MTX [179] . CyA is particularly effective in MAS, a potentially lifethreatening complication occurring in 7-13 % of sJIA patients. Evidence of CyA efficacy in MAS associated with sJIA relies upon observational studies and case series (Table 10 ). CyA has been proven to result in clinical improvement in most patients, being particularly effective in the management of systemic symptoms [180] [181] [182] [183] [184] [185] [186] [187] . Importantly, CyA has been reported life-saving in serious cases of steroid-resistant MAS [180] .
Cyclosporine A and Hepatitis C Virus
CyA has been reported to suppress the replication of hepatitis C virus (HCV) both in vitro and in vivo, in a dose-dependent manner [188] . Such effect is mediated by the inhibition of cyclophillin B [189] . The maximum inhibitory effect exerted by CyA is similar to that of IFN-α; to note, these two agents are certainly additive and possibly synergistic [190] . In addition CyA displays an anti-fibrotic effect inhibiting collagen production and increasing collagenase activity in hepatic stellate cells [191] . These data account for the safety and efficacy of CyA in the treatment of patients with autoimmune disorders and concomitant chronic HCV infection, as documented by some case series with improvement of liver function and decreased viral load [192, 193] . Furthermore, CyA safety in HCV-positive RA patients has been evaluated in combination with anti-TNF-α agents, without any significant adverse event [194] .
Cyclosporine A and Pregnancy
CyA, being highly lipophilic, crosses the placenta to achieve in the foetal circulation a 10-50 % concentration of that in maternal plasma. Animal studies have not shown increased malformation rates, but in utero exposure to CyA in rabbits induces a nephron reduction leading to systemic hypertension and progressive chronic renal insufficiency in adulthood [195] . These in vivo observations explain why the FDA currently classifies CyA in the pregnancy risk category C. Data on CyA in pregnancies are mostly derived from registries of pregnant transplant recipients, with more than 5000 observed pregnancies. Most studies of pregnancies exposed to CyA have concluded that there is no evidence for teratogenicity. On the other hand, an increase in premature delivery and low birth weight has been described, with 56 and 43 % prevalence rates in a meta-analysis of 15 studies [196] . It is still not clear whether prematurity and low birth weight are actually due to CyA therapy or rather related to the underlying disease. Conversely, experience in pregnant patients with autoimmune disease is limited to case reports and case series accounting for about 50 pregnancies. No increase of congenital malformations or any particular malformation pattern has emerged; however, a higher incidence of low birth weight and prematurity has been described in CyA-treated women with autoimmune diseases as compared with the general population, even though to a lesser extent than in transplanted women [197] . A 12-year follow-up of 175 children exposed to CyA in utero has showed a 16 % incidence of mental developmental delay, which might be attributed to the high incidence of prematurity [198] . Other studies have shown that maternal treatment with CyA during pregnancy does not permanently affect the foetal immune system [199, 200] . As a whole, CyA is considered to be safe during pregnancy, therefore treatment can be continued at the lowest effective dose throughout the entire gestation. A periodic control of maternal blood pressure and renal function should be performed on a regular basis.
Cyclosporine A and Breastfeeding
CyA is excreted in breast milk, with a wide variation in the milk-to-maternal serum concentration ratio, depending on the time of sampling and maternal dose. To date, evidence on the safety of breastfeeding during CyA therapy is limited to small case series and case reports [201, 202] . No adverse events related to maternal CyA treatment during lactation have been described, with CyA being undetectable in almost all cases. Even though these data are reassuring, evidence is limited and still inconclusive. Breastfeeding during CyA treatment is not currently recommended because of theoretical risks of immunosuppressive effects in the neonate [203] .
Side Effects
In a study involving 154 patients with RA, a dose-related decrease in glomerular filtration rate with corresponding increase in serum creatinine has emerged as the most frequently reported side effect of CyA (48 %); after drug discontinuation, creatinine returns within 15 % of baseline in almost all cases [204] . There is a wide variety in the incidence of new-onset arterial hypertension, which ranges from 0 to 57 % across available studies. Gastrointestinal symptoms, including nausea, abdominal pain, diarrhoea and vomiting, have been described in less than 5 %. Hepatotoxicity (presenting as elevation of hepatic enzymes and bilirubin) usually occurs at higher dosages than those used in rheumatology. Neurologic side effects of CyA include headache, tremor, seizure psychosis, paraesthesias, and sleep disturbances; paraesthesias and tremor can occur in up to 40 % of patients. Gingival hyperplasia has been reported in up to 30 % of patients on CyA; cutaneous side effects comprise hypertrichosis, epidermal cyst, keratosis pilaris and sebaceous hyperplasia. Hypertrichosis is rather frequent, presenting in up to 60 % of patients. Hyperlipidemia, in particular hypertriglyceridemia, can present in up to 15 % of patients [205, 206] . Based on epidemiologic analyses, FDA warns about a relationship between CyA and malignant lymphomas among RA patients and about an increased hazard of skin and lymphoproliferative malignancies among patients with psoriasis receiving CyA, even though the relative risk is similar to subjects treated with other immunosuppressive agents [207] . To date, there is no evidence that CyA predisposes to solid malignancies; large controlled studies have even suggested an immunoprotective action of CyA with a decreased OR for breast and colon neoplasias [204] . Table 11 reports the toxicity profile of CyA in RA patients. Table 12 reports the pharmacological compounds interfering with CyA pharmacokinetics. As CyA is mainly metabolised by cytochrome P450, drugs that induce hepatic enzyme metabolism lower CyA concentrations, while drugs that inhibit hepatic metabolism raise CyA blood concentrations. Older age, concomitant renal failure, arterial hypertension and dehydration might also contribute to enhance the nephrotoxicity of CyA [206] .
Drug Interactions

Drug Safety Monitoring
Due to CyA nephrotoxicity, serum creatinine and blood pressure should be checked on at least two occasions to obtain a baseline value prior to therapy. Both creatinine and blood pressure should be monitored fortnightly during the first 3 months of treatment and monthly thereafter. Dose reduction of 0.5-0.75 mg kg −1 day −1 is warranted if serum creatinine increases above baseline by 30 %-even if still in the normal range-or if uncontrolled hypertension supervenes. When creatinine increases by more than 50 % of baseline, the daily dose dosage should be reduced by 50 %; if this reduction does not affect the creatinine value, the drug should be discontinued. If arterial hypertension develops, the use of anti-hypertensive Given that in patients with autoimmune diseases a poor correlation between CyA blood levels and its clinical effect has been noted, the monitoring of CyA plasma concentration is not routinely required [205, 206] .
Conclusion
CyA exerts a valid immunomodulator action, being effective in the treatment of many autoimmune diseases. Even though novel therapeutic tools have emerged over the recent years, CyA still represents a suitable option in several clinical settings:
(a) In SLE, refractory lupus nephritis and cytopenias have been reported to respond well to CyA; (b) In PsA, CyA can be listed as a therapeutic option, being rather effective in cutaneous disease; (c) In BD, CyA is a valued treatment tool in the management of uveitis and thrombophlebitis; (d) In adult onset Still's disease, treatment with CyA can be considered for the most severe complications such as disseminated intravascular coagulation and MAS; (e) In dry eye disease, topical CyA has been proven to be beneficial; (f) In inflammatory myopathies, CyA is currently regarded as a second-line option to be reserved to patients with disease refractory to standard regimen; (g) In paediatric rheumatology, CyA is used in the management of JDM and MAS associated with sJIA.
Conversely, CyA seems to exert an overall poor beneficial effect in SSc, Sjogren's syndrome and systemic vasculitides. CyA can be considered as an anchor drug in particular clinical situations:
(a) HCV-positive patients: CyA has been shown to suppress the replication of HCV, and it can thus be administered to those patients with HCV; (b) Pregnancy: CyA can be safely prescribed throughout the gestation course, providing a pharmacological option in pregnant women with an active autoimmune disease.
Surely caution should be paid to CyA safety profile, in particular because of its nephrotoxicity: prescribing this drug should be avoided in patients with a raised baseline creatinine level and uncontrolled hypertension. Unfortunately, most of available evidence about CyA efficacy in rheumatology comes from small and uncontrolled studies, with very few RCT. Nevertheless, available data are encouraging, supporting CyA as a corticosteroid-sparing action in many rheumatologic conditions: despite being regarded as an Boutof-fashion^drug, CyA should be still part of therapeutic armamentarium of rheumatologists, even in 2016.
